Consolidation therapy with high-dose cyclophosphamide (HDC) reduces minimal residual disease in patients with chronic lymphocytic leukemia (CLL) treated with fludarabine as induction therapy.

被引：0
|
作者：
Weiss, M [1 ]
Glenn, M [1 ]
Maslak, P [1 ]
Rahman, Z [1 ]
Megherian, L [1 ]
Noy, A [1 ]
Zelenetz, A [1 ]
Scheinberg, D [1 ]
Golde, D [1 ]
机构：
[1] MEM SLOAN KETTERING CANC CTR,DIV HEMATOL ONCOL,NEW YORK,NY 10021
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1911 / 1911
页数：1
相关论文
共 50 条
  • [41] Improved survival in patients with relapsed - Refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination.
    Wierda, W
    O'Brien, S
    Faderl, S
    Ferrajoli, A
    Lerner, S
    Wang, XM
    Thomas, D
    Garcia-Manero, G
    Cortes, J
    Kantarjian, H
    Keating, M
    BLOOD, 2003, 102 (11) : 110A - 110A
  • [42] AN ASSESSMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE ELIGIBLE FOR FIRST-LINE THERAPY BUT UNSUITABLE FOR FULL-DOSE FLUDARABINE
    Jeyakumaran, D.
    Cote, S.
    Kempel-Waibel, A.
    HAEMATOLOGICA, 2016, 101 : 724 - 724
  • [43] CHEMOIMMUNOTHERAPY REGIMEN OF FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB FOLLOWED BY ALEMTUZUMAB AS INITIAL THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A VALID APPROACH FOR ERADICATION OF MINIMAL RESIDUAL DISEASE
    Galimberti, S.
    Cecconi, N.
    Cervetti, G.
    Buda, G.
    Orciuolo, E.
    Papineschi, F.
    Caracciolo, F.
    Benedetti, E.
    Petrini, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 38 - 38
  • [44] Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia
    Foon, Kenneth A.
    Boyiadzis, Michael
    Land, Stephanie R.
    Marks, Stanley
    Raptis, Anastasios
    Pietragallo, Louis
    Meisner, Dennis
    Laman, Andrew
    Sulecki, Mathew
    Butchko, Allyson
    Schaefer, Patricia
    Lenzer, Diana
    Tarhini, Ahmad
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 498 - 503
  • [45] Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete Responses
    Lamanna, Nicole
    Jurcic, Joseph G.
    Noy, Ariela
    Maslak, Peter
    Gencarelli, Alison N.
    Panageas, Katherine S.
    Heaney, Mark L.
    Brentjens, Renier J.
    Golde, David W.
    Scheinberg, David A.
    Zelenetz, Andrew D.
    Weiss, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 491 - 497
  • [46] Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: A study by the German CLL Study Group
    Eichhorst, Barbara F.
    Busch, Raymonde
    Obwandner, Tanja
    Kuhn-Hallek, Ingrid
    Herschbach, Peter
    Hallek, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1722 - 1731
  • [47] Correlation between Campath-1H and response to therapy in patients with chronic lymphocytic leukemia treated for minimal residual disease.
    Albitar, M
    Manshouri, T
    Giles, F
    Kantarjian, HM
    Keating, MJ
    O'Brien, S
    BLOOD, 2002, 100 (11) : 804A - 804A
  • [48] Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia
    Foon, Kenneth A.
    Mehta, Dhaval
    Lentzsch, Suzanne
    Kropf, Patricia
    Marks, Stanley
    Lenzner, Diana
    Pietragallo, Louis
    Sulecki, Mathew
    Tarhini, Ahmad
    Boyiadzis, Michael
    BLOOD, 2012, 119 (13) : 3184 - 3185
  • [49] Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101
    Lin, Thomas S.
    Donohue, Kathleen A.
    Byrd, John C.
    Lucas, Margaret S.
    Hoke, Eva
    Bengtson, Elizabeth M.
    Atkins, James N.
    Link, Brian K.
    Rai, Kanti R.
    Larson, Richard A.
    BLOOD, 2009, 114 (22) : 92 - 92
  • [50] Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL)
    Akhtar, Othman S.
    Attwood, Kristopher
    Lund, Ian
    Hare, Ryan
    Hernandez-Ilizaliturri, Francisco J.
    Torka, Pallawi
    LEUKEMIA & LYMPHOMA, 2019, 60 (07) : 1650 - 1655
12345